Use of hormone replacement therapy among cardiac patients at a Canadian academic centre

M R Wise1, D E Stewart, P Liu

  • 1Division of Cardiology, Toronto Hospital, Faculty of Medicine, University of Toronto, Ont.

Insights

Few post-menopausal women at high risk for coronary artery disease (CAD) use hormone replacement therapy (HRT). Better documentation and adherence to optimal practices are needed for managing these women.

Area of Science:

  • Cardiology
  • Endocrinology
  • Women's Health

Background:

  • Hormone replacement therapy (HRT) is linked to reduced coronary artery disease (CAD) risk.
  • HRT use remains low among post-menopausal women despite its benefits.
  • This study investigates HRT utilization in women at high risk for CAD.

Purpose of the Study:

  • To determine the prevalence of HRT use in post-menopausal women attending a cardiology clinic.
  • To identify predictors of HRT use in this high-risk population.

Main Methods:

  • Cross-sectional survey of post-menopausal women at a Toronto teaching hospital (Jan 1996 - Aug 1997).
  • Data collected via chart review and telephone interviews with patients or physicians.
  • Multivariate logistic regression used to identify HRT use predictors.

Main Results:

  • 80 women with CAD risk factors or diagnosis were included.
  • HRT use was documented in only 21% of charts; 22% were current users.
  • Younger women were more likely to use HRT (OR 0.91, p<0.05); CAD risk profile and hysterectomy history were not associated.
  • Contraindications to HRT were present in 24% of never-users and 29% of current/past users.

Conclusions:

  • Significant lack of HRT use documentation in patient charts.
  • Low current HRT utilization among women at high risk for CAD.
  • Highlights the need for improved management strategies and adherence to best practices for cardiovascular risk reduction in women.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...